Collaborative Drug Therapy Management (CDTM)

Collaborative Drug Therapy Management (CDTM) allows qualified pharmacists to engage in a formal collaborative practice arrangement with a physician, so long as the pharmacist is practicing in facilities regulated by article twenty-eight of the public health law, including any diagnostic center, treatment center, or hospital-based outpatient departments (including outpatient clinics). This protocol-based arrangement, after being given consent by the patient, allows the pharmacist to adjust or manage a drug regimen for a specific disease or disease state.

CDTM has been successfully used throughout New York to improve patient care outcomes, improve medication adherence and decrease health care costs. The authority to engage in CDTM is set to sunset by July, 2020. Please inform your legislators of the importance of CDTM! Having to combat unnecessary sunset every two years is potentially stopping the robust development of these needed services. See fact sheet below.

Collaborative Drug Therapy Management (CDTM)

2019 CDTM Fact Sheet
CDTM Extension Signed Into Law (2015)
CDTM Bill Text (2019)
2015 CDTM Lobbying Presentation
2014 May CDTM Executive Summary
CDTM Video

CDTM Example Documents:
CDTM Outcomes Data Collection Instructions
CDTM Outcome Spreadsheet
Consent Forms
Anticoagulation Service Collaborative Practice Agreement

CDTM Summit II – 2/27/[email protected] (Reference Documents):

Development of a CDTM Practice
Successful Implementation in Management of a CDTM Ambulatory Practice
Clinical Pearls:  Challenges in Managing a Collaborative Heart Failure Clinic
Clinical Peals:  Antimicrobials
An Update of the CDTM Law & Update on Outcomes Data and Metrics